PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 208 participants.

Also called NCT03808376

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Not applicable
Enrolled
  • 208 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03808376
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03808376. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-12-27 (actual); primary completion 2020-05-08 (actual). Results posted on 2024-08-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
Acronym
PROMISE
Condition
Diabetes Mellitus
Condition
Diabetes Mellitus, Type 1
Condition
Diabetes Mellitus, Type 2
Intervention (Device)
Continuous Glucose Monitoring System
Lead sponsor
Senseonics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03808376
Content hash
bc2dc90ad87e5f4556986379e4cab39432062e6b5c32b8b032399cf3095951a2